Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bcl2 like 13 (BCL2L13) is an outer mitochondrial membrane-anchored transmembrane protein functioning as a receptor for mitophagy in mammalian cells. It contains two LC3-interacting regions (LIRs) enabling direct interaction with autophagy effectors such as LC3B, GABARAP, and ULK1. BCL2L13 acts independently of the canonical PINK1-Parkin pathway and orchestrates the selective removal of damaged mitochondria by recruiting autophagy machinery, particularly in response to mitochondrial depolarization or metabolic stress. The MEKK3-MEK5-ERK5 signaling axis is additionally identified as a novel regulator promoting mitophagy under basal, non-damage conditions, though its molecular details as a drug target remain under investigation[1][2][3].
Recruitment of autophagy-related proteins (e.g., LC3B, GABARAP) via LC3-interacting region (LIR) Formation of LC3B/ULK1/BCL2L13 complex for mitophagy induction Phosphorylation-dependent regulation of autophagy machinery engagement[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bcl2 like 13 (BCL2L13).